Overview |
bs-10129R-Cy5 |
P21 Polyclonal Antibody, Cy5 Conjugated |
WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
Human, Mouse, Rat, Sheep |
Dog, Rabbit |
Specifications |
Cy5 |
Rabbit |
KLH conjugated synthetic peptide derived from human P21 |
21-100/164 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
1026 |
P38936 |
Cytoplasm, Nucleus |
P21; CIP1; SDI1; WAF1; CAP2; CDKN1; MDA-6; p21CIP1; Cyclin-dependent kinase inhibitor 1; CDK-interacting protein 1; Melanoma differentiation-associated protein 6; CDKN1A; MDA6; PIC1 |
May be the important intermediate by which p53/TP53 mediates its role as an inhibitor of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex. |
Application Dilution |
WB |
1:300-5000 |
FCM |
1:20-100 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |